tradingkey.logo

Check Cap Ltd

CHEK

0.684USD

+0.007+1.08%
Market hours ETQuotes delayed by 15 min
4.01MMarket Cap
LossP/E TTM

Check Cap Ltd

0.684

+0.007+1.08%
More Details of Check Cap Ltd Company
Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. It's capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. C-Scan is non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
Company Info
Ticker SymbolCHEK
Company nameCheck Cap Ltd
IPO dateFeb 19, 2015
CEOMr. Alex Ovadia
Number of employees- -
Security typeOrdinary Share
Fiscal year-endFeb 19
Address29 Abba Hushi Ave.
City
Stock exchangeNASDAQ Capital Market Consolidated
CountryIsrael
Postal code3009000
Phone97248303401
Websitehttps://check-cap.com/
Ticker SymbolCHEK
IPO dateFeb 19, 2015
CEOMr. Alex Ovadia
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Boaz Shpigelman
Mr. Boaz Shpigelman
Vice President - Research and Development
Vice President - Research and Development
1.23K
+1.49%
Mr. XiangQian (XQ) Lin
Mr. XiangQian (XQ) Lin
Independent Director
Independent Director
950.00
--
Mr. Alex Ovadia
Mr. Alex Ovadia
Chief Executive Officer
Chief Executive Officer
752.00
--
Ms. Clara Ezed
Ms. Clara Ezed
Independent Director
Independent Director
211.00
--
Mr. Steven J. Hanley
Mr. Steven J. Hanley
Chairman of the Board
Chairman of the Board
--
--
Dr. Yoav Kimchy, Ph.D.
Dr. Yoav Kimchy, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Israel Hershko
Mr. Israel Hershko
Vice President - Quality Assurance and Regulatory Affairs
Vice President - Quality Assurance and Regulatory Affairs
--
--
Mr. Yuval Yanai
Mr. Yuval Yanai
Independent Director
Independent Director
--
--
Dr. Hanit Brenner-lavie
Dr. Hanit Brenner-lavie
Vice President - Clinical Affairs
Vice President - Clinical Affairs
--
--
Mr. Dan Hilerowitz
Mr. Dan Hilerowitz
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Boaz Shpigelman
Mr. Boaz Shpigelman
Vice President - Research and Development
Vice President - Research and Development
1.23K
+1.49%
Mr. XiangQian (XQ) Lin
Mr. XiangQian (XQ) Lin
Independent Director
Independent Director
950.00
--
Mr. Alex Ovadia
Mr. Alex Ovadia
Chief Executive Officer
Chief Executive Officer
752.00
--
Ms. Clara Ezed
Ms. Clara Ezed
Independent Director
Independent Director
211.00
--
Mr. Steven J. Hanley
Mr. Steven J. Hanley
Chairman of the Board
Chairman of the Board
--
--
Dr. Yoav Kimchy, Ph.D.
Dr. Yoav Kimchy, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
EquityLine Alternate Assets GP Inc
13.04%
Symetryx Corp
5.79%
J.P. Morgan Securities LLC
0.60%
Citadel Advisors LLC
0.36%
BNP Paribas Securities Corp. North America
0.34%
Other
79.87%
Shareholders
Shareholders
Proportion
EquityLine Alternate Assets GP Inc
13.04%
Symetryx Corp
5.79%
J.P. Morgan Securities LLC
0.60%
Citadel Advisors LLC
0.36%
BNP Paribas Securities Corp. North America
0.34%
Other
79.87%
Shareholder Types
Shareholders
Proportion
Corporation
18.83%
Research Firm
1.02%
Hedge Fund
0.55%
Investment Advisor/Hedge Fund
0.20%
Individual Investor
0.08%
Other
79.32%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
39
1.57M
26.85%
+1.07M
2025Q1
42
1.57M
26.85%
+1.00M
2024Q4
44
1.61M
27.59%
+1.15M
2024Q3
45
1.48M
25.29%
+968.05K
2024Q2
48
1.48M
25.22%
+958.50K
2024Q1
57
722.40K
12.35%
+185.59K
2023Q4
59
777.23K
13.29%
+83.98K
2023Q3
61
699.06K
11.95%
+309.38K
2023Q2
62
22.37K
0.38%
-595.96K
2023Q1
68
336.11K
6.40%
-190.75K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
EquityLine Alternate Assets GP Inc
762.72K
13.04%
+762.72K
--
Apr 05, 2024
Symetryx Corp
338.63K
5.79%
+37.76K
+12.55%
Nov 27, 2023
J.P. Morgan Securities LLC
35.36K
0.6%
+33.86K
+2257.07%
Mar 31, 2025
Citadel Advisors LLC
20.85K
0.36%
-1.68K
-7.46%
Mar 31, 2025
BNP Paribas Securities Corp. North America
19.84K
0.34%
+6.20K
+45.46%
Mar 31, 2025
Two Sigma Investments, LP
11.48K
0.2%
+11.48K
--
Mar 31, 2025
Dimensional Fund Advisors, L.P.
8.96K
0.15%
--
--
Jan 31, 2025
Morgan Stanley & Co. LLC
3.90K
0.07%
-26.90K
-87.33%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.93K
0.05%
--
--
May 31, 2025
Shpigelman (Boaz)
1.23K
0.02%
+18.00
+1.49%
Apr 01, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 23, 2022
Merger
20<1
Nov 23, 2022
Merger
20<1
Nov 23, 2022
Merger
20<1
Nov 23, 2022
Merger
20<1
Date
Type
Ratio
Nov 23, 2022
Merger
20<1
Nov 23, 2022
Merger
20<1
Nov 23, 2022
Merger
20<1
Nov 23, 2022
Merger
20<1
KeyAI